



rivfloza[®]
(nedosiran) injection
80mg, 128mg, 160mg

Rivfloza[®] dosing and administration guide



Rivfloza[®] is an RNAi therapy designed to reduce levels of hepatic LDH enzyme and reduce the overproduction of oxalate by the liver.¹

LDH=lactate dehydrogenase; RNAi=RNA interference.

Indication and Usage

Rivfloza[®] (nedosiran) injection 80 mg, 128 mg, or 160 mg is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, eg, eGFR \geq 30 mL/min/1.73 m².

Important Safety Information

Adverse Reactions

Most common adverse reactions (reported in 39% of patients) are injection site reactions, which include erythema, pain, bruising, and rash.

Please see Important Safety Information throughout.



Please [click here](#) for RIVFLOZA[®] Prescribing Information.

Rivfloza® dosing

Rivfloza® is provided as a **prefilled syringe (fixed dose)** or **single-dose vial**.¹

- Rivfloza® is **administered once monthly via subcutaneous injection**
- Dosing is based on age and actual body weight
- No loading dose or titration schedule required



Dosing regimen in adults and adolescents aged 12 years and older¹

Body weight	Dosing regimen
≥110 lbs (≥50 kg)	160 mg once monthly (prefilled syringe, 1 mL) 
<110 lbs (<50 kg)	128 mg once monthly (prefilled syringe, 0.8 mL) 



When administering Rivfloza® using a **single-dose vial**, use 2 Rivfloza® vials if the dose is ≥0.6 mL.

Dosing regimen in children aged 9 to 11 years¹

Body weight	Dosing regimen
≥110 lbs (≥50 kg)	160 mg once monthly (prefilled syringe, 1 mL) 
<110 lbs (<50 kg)	3.3 mg/kg once monthly, not to exceed 128 mg (Vial, dose volume rounded to nearest 0.1 mL) 

Important Safety Information

Adverse Reactions

Most common adverse reactions (reported in 39% of patients) are injection site reactions, which include erythema, pain, bruising, and rash.

Please see Important Safety Information throughout.
Please [click here](#) for RIVFLOZA® Prescribing Information.

Missed doses¹

- In the case of a missed dose, administer Rivfloza® as soon as possible
- **If the planned dose is missed by >7 days**, administer Rivfloza® as soon as possible and resume monthly dosing from the most recently administered dose

 **rivfloza®**
(nedosiran) injection
80mg, 128mg, 160mg

Rivfloza® administration



At-home administration

- Rivfloza® can be self-administered or caregiver-administered at home via single-dose prefilled syringe or vial¹



Prefilled syringe

- For patients aged 12 years and older, the patient, caregiver, or a healthcare provider may administer Rivfloza® using the prefilled syringe¹
- For children aged 9 to 11 who weigh ≥ 110 lbs (≥ 50 kg), a caregiver or healthcare provider may administer Rivfloza® using the prefilled syringe¹

See Rivfloza® *Instructions for Use* for **single-dose, prefilled syringe** in [Prescribing Information](#).



Single-dose vial

- Rivfloza® single-dose vials are intended for use under the **guidance and supervision** of a healthcare provider¹
- For children aged 9 to 11 years who weigh < 110 lbs (< 50 kg), Rivfloza® may be administered from a vial by a caregiver after proper training, if a healthcare provider determines that it is appropriate, and with medical follow-up as necessary¹

See Rivfloza® *Instructions for Use* for **single-dose vial** in [Prescribing Information](#).



Rivfloza® storage and handling

Rivfloza® is available in single-dose prefilled syringes and single-dose vials in cartons.¹



Storage conditions¹

Refrigerated 36°F to 46°F (2°C to 8°C)	Room temperature 59°F to 86°F (15°C to 30°C)
Until expiration date	Maximum 28 days (4 weeks)



Do not freeze Rivfloza®



Store in original carton, away from direct heat and light



Rivfloza® vials are for one-time use only. Do not reuse the Rivfloza® vial and discard any unused medication

Important Safety Information

Adverse Reactions

Most common adverse reactions (reported in 39% of patients) are injection site reactions, which include erythema, pain, bruising, and rash.

Please see Important Safety Information throughout.

Please [click here](#) for RIVFLOZA® Prescribing Information.

 **rivfloza®**
(nedosiran) injection
80mg, 128mg, 160mg



 **rivfloza**[®]
(nedosiran) injection
80mg, 128mg, 160mg

VISIT RivflozaPro.com >



Indication and Usage

Rivfloza[®] (nedosiran) injection 80 mg, 128 mg, or 160 mg is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, eg, eGFR \geq 30 mL/min/1.73 m².

Important Safety Information

Adverse Reactions

Most common adverse reactions (reported in 39% of patients) are injection site reactions, which include erythema, pain, bruising, and rash.

Please see Important Safety Information throughout.

Please [click here](#) for RIVFLOZA[®] Prescribing Information.

Reference: 1. Rivfloza[®] [package insert]. Plainsboro, NJ: Novo Nordisk Inc.

Rivfloza[®] is a registered trademark of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2024 Novo Nordisk All rights reserved. US24RVZA00057 May 2024

